TC
ATNM icon

TFS Capital’s Actinium Pharmaceuticals ATNM Stock Holding History

TFS Capital’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,563
Closed -$116K – 902
2015
Q1 		$116K Sell
1,563
-639
-29% -$76K 0.01% 863
2014
Q4 		$389K Buy
+2,202
New +$418K 0.04% 655

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TFS Capital's ATNM Position: Q2 2015 in Review

TFS Capital sold out of Actinium Pharmaceuticals (ATNM) in Q2 2015, closing a stake of 1,563 shares — an estimated $116K sold.

TFS Capital first reported a position in ATNM in Q4 2014 and held it in 2 quarters. The position peaked at $389K in Q4 2014. 39 funds tracked by Wall St. Rank hold ATNM as of Q2 2015.

  • TFS Capital reported no remaining Actinium Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • TFS Capital sold 1,563 Actinium Pharmaceuticals shares in Q2 2015, an estimated $116K.
  • TFS Capital first reported a position in Actinium Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • TFS Capital's Actinium Pharmaceuticals position peaked at $389K in Q4 2014.
  • 39 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2015.

Based on TFS Capital's 13F filing for Q2 2015, filed 5 Aug 2015.